Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-11T23:34:15.297Z Has data issue: false hasContentIssue false
  • English
  • Français

The “Good Enough” Mood Stabilizer: A Review of the Clinical Evidence

Published online by Cambridge University Press:  07 November 2014

David Kahn  and
Rebecca Chaplan
Get access Rights & Permissions [Opens in a new window]

Abstract

A growing family of medications is used for mood stabilization in bipolar disorder. These medications fall into two broad categories according to likely mechanisms of action. Within the categories, specific drugs may vary in their efficacy for different phases of the disorder. The first category, including lithium, anticonvulsants, and some novel treatments, appears to have mechanisms related to intracellular second messengers. These medications have more pronounced antimanic than antidepressant effects, except for lamotrigine, which has antidepressant effects without precipitating mania. The second group of mood stabilizers is the atypical antipsychotics, which act through dopamine and other monoamines. Olanzapine and in all likelihood other drugs in the class possess marked, acute antimanic properties and possible antidepressant properties, but require further study before they can be used as routine options in long-term care. It is clear that the advent of multiple mood stabilizer candidates has not yet led to a single ideal therapy for bipolar disorder, but rather to options that can be flexibly tailored to the lifetime needs of individual patients, in sequences or combinations, and perhaps in conjunction with other classes of psychotropics.

Type
Feature Article
Information
CNS Spectrums , Volume 7 , Issue 3 , March 2002 , pp. 227 - 237
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Sachs, GS, Printz, DJ, Kahn, DA, Carpenter, D, Docherty, JP. The expert consensus guideline series: medication treatment of bipolar disorder. Postgrad Med. 2000;4:1–104.Google Scholar
2.West, JC, Das, A, Kahn, DA, et al. The treatment of bipolar disorder in routine practice. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.Google Scholar
3.Sachs, GS. Treatment-resistant bipolar depression. Am J Psychiatry. 1996;19:215–236.Google ScholarPubMed
4.American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(suppl 12):1–36.CrossRefGoogle Scholar
5.Post, RM. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr Res. 1999;39:153–158.CrossRefGoogle ScholarPubMed
6.Ghaemi, SN, Boiman, EE, Goodwin, FK. Kindling and second messengers: an approach to the neurobiology of recurrence in bipolar disorder. Biol Psychiatry. 1999;45:137–144.CrossRefGoogle Scholar
7.Bazil, CW, Pedley, TA. Advances in the medical treatment of epilepsy. Annu Rev Med. 1998;49:135–162.CrossRefGoogle ScholarPubMed
8.Ure, JA, Perassolo, M. Update on the pathophysiology of the epilepsies. J Neurol Sci. 2000;177:1–17.CrossRefGoogle ScholarPubMed
9.Manji, HK, Lenox, RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry. 2000;48:518–530.CrossRefGoogle ScholarPubMed
10.Devanand, DP, Polanco, P, Cruz, R, et al.The efficacy of ECT in mixed affective states. J ECT. 2000;16:32–37.CrossRefGoogle ScholarPubMed
11.Rush, AJ, Post, RM, Nolen, WA, et al.Methodological issues in developing new acute treatments for patients with bipolar illness. Biol Psychiatry. 2000;48:615–624.CrossRefGoogle ScholarPubMed
12.French, JA. The art of antiepileptic trial design. Adv Neurol. 1998;76:113–123.Google ScholarPubMed
13.Kupka, RW, Nolen, WA, Altshuler, LL, et al.The Stanley Foundation Bipolar Network: 2. Preliminary comment of demographics, course of illness and response to novel treatments. Br J Psychiatry. 2001;178:S177–S183.CrossRefGoogle Scholar
14.Young, LT, Joffe, RT, Robb, JC, MacQueen, GM, Marriott, M, Patelis-Siotis, I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000;157:124–126.CrossRefGoogle Scholar
15.Nemeroff, CB, Evans, DL, Gyulai, L, et al.Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–912.CrossRefGoogle ScholarPubMed
16.Goodwin, FK, Jamison, KR. Medical treatment of manic episodes. In: Goodwin, FK, Jamison, KR, eds. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:603–629.Google Scholar
17.Prien, RF, Himmelhoch, JM, Kupfer, DJ. Treatment of mixed mania. J Affect Disord. 1988;15:9–15.CrossRefGoogle Scholar
18.Goodwin, FK, Jamison, KR. Medical treatment of acute bipolar depression. In: Goodwin, FK, Jamison, KR, eds. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:630–664.Google Scholar
19.Prien, RF, Caffey, EM Jr, Klett, CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1973;28:337–341.CrossRefGoogle ScholarPubMed
20.Prien, RF, Klett, CJ, Caffey, EM Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry. 1973;29:420–425.CrossRefGoogle ScholarPubMed
21.Davis, JM. Overview: maintenance therapy in psychiatry: II. Affective disorders. Am J Psychiatry. 1976;133:1–13.Google ScholarPubMed
22.Dunner, DL, Stallone, F, Fieve, RR. Prophylaxis with lithium carbonate: an update. Arch Gen Psychiatry. 1982;39:1344–1345.Google ScholarPubMed
23.Dunner, DL, Fieve, RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974;30:229–233.CrossRefGoogle ScholarPubMed
24.Dunner, DL, Patrick, V, Fieve, RR. Rapid cycling manic depressive patients. Compr Psychiatry. 1977;18:561–566.CrossRefGoogle ScholarPubMed
25.Swann, AC, Bowden, CL, Morris, D, et al.Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54:37–42.CrossRefGoogle ScholarPubMed
26.Calabrese, JR, Markovitz, PJ, Kimmel, SE, Wagner, SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol. 1992;12(suppl 1):53S–56S.CrossRefGoogle ScholarPubMed
27.Winsberg, ME, De Golia, SG, Strong, CM, et al. Divalproex in medicationnaïve bipolar II depression. Paper presented at: the Annual Meeting of the American Psychiatric Association; May 1997; San Diego, Calif.Google Scholar
28.Bowden, CL, Calabrese, JR, McElroy, SL, et al.A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481–489.CrossRefGoogle ScholarPubMed
29.Orsini, CMJ, Frankle, WG, Grandin, LD, et al. Lithium versus valproic acid: a comparison of the long-term treatment of bipolar illness. Paper presented at: the Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.Google Scholar
30.Calabrese, JR, Shelton, MD, Bowden, CL, et al.Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry. 2001;62(suppl 14):34–41.Google ScholarPubMed
31.Ballenger, JC, Post, RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol. 1978;2:159–175.Google ScholarPubMed
32.Keck, PE Jr, McElroy, SL, Nemeroff, CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci. 1992;4;395–405.Google ScholarPubMed
33.Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. Correlates of antimanic response to carbamazepine. Psychiatry Res. 1987;21:71–83.CrossRefGoogle ScholarPubMed
34.Kahn, D. Carbamazepine and other antiepileptic drugs in refractory depression. In: Roose, SP, Glassman, AH, eds. Treatment Strategies for Refractory Depression. Washington, DC: American Psychiatric Press; 1990:75–108.Google Scholar
35.Keck, PE, McElroy, SL. Antiepileptic drugs. In: Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:431–454.Google Scholar
36.Post, RM, Leverich, GS, Rosoff, AS, Altshuler, LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol. 1990;10:318–327.CrossRefGoogle ScholarPubMed
37.Denicoff, KD, Smith-Jackson, EE, Disney, ER, Ali, SO, Leverich, GS, Post, RM. Comparative efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470–478.CrossRefGoogle ScholarPubMed
38.Frye, M, Ketter, TA, Kimbrell, TA, et al.A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607–614.CrossRefGoogle ScholarPubMed
39.Bowden, C, Calabrese, JR, Asher, J. Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double-blind, placebo-controlled studies. Paper presented at: 39th Annual Meeting of American College of Neuropsychopharmacology; December 2000; San Juan, Puerto Rico.Google Scholar
40.Anand, A, Oren, DA, Berman, A, et al. Lamotrigine treatment of lithium failure outpatient—a double-blind, placebo-controlled study. Paper presented at: Third International Conference on Bipolar Disorder; June 1999; Pittsburgh, Pa.Google Scholar
41.Berk, M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol. 1999;9:S119–S123.CrossRefGoogle ScholarPubMed
42.Calabrese, JR, Bowden, CL, McElroy, SL, et al.Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999;156:1019–1023.CrossRefGoogle ScholarPubMed
43.Calabrese, JR, Bowden, CL, DeVeaugh-Geiss, J, et al. Lamotrigine demonstrates long-term mood stabilization in manic patients. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.CrossRefGoogle Scholar
44.Calabrese, JR, Suppes, T, Bowden, CL, et al.A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–850.CrossRefGoogle ScholarPubMed
45.Suppes, P, Ascher, J, Bowden, CL. Lamotrigine in rapid-cycling bipolar disorder: predictors of response. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.Google Scholar
46.Altshuler, LL, Keck, PE Jr, McElroy, SL. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord. 1999;1:61–65.CrossRefGoogle ScholarPubMed
47.Ghaemi, SN, Goodwin, FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord. 2001;65:167–171.CrossRefGoogle ScholarPubMed
48.Pande, AC, Crockatt, JG, Janney, CA, et al.Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin bipolar disorder study group. Bipolar Disord. 2000;2:249–255.CrossRefGoogle ScholarPubMed
49.The Editors. Our readers answer [letter]. Psychiatry Drug Alerts. 2001;7:56.Google Scholar
50.Chengappa, R, Rathore, D, Levine, D, et al.Topiramate as add-on treatment of patients with bipolar mania. Bipolar Disord. 1999;1:42–53.CrossRefGoogle ScholarPubMed
51.McElroy, SL, Suppes, T, Keck, PE, et al.Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;47:1025–1033.CrossRefGoogle ScholarPubMed
52.Grunze, HCR, Normann, C, Langosch, J, et al.Antimanic efficacy of topiramate in an open trial with an on-off-on design. J Clin Psychiatry. 2001;62:464–468.CrossRefGoogle Scholar
53.Calabrese, JR, Keck, PE Jr, McElroy, SL, Shelton, MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol. 2001;21:340–342.CrossRefGoogle ScholarPubMed
54.Hussain, MX, Chaudry, ZA, Hussain, S. Topiramate in treatment of refractory bipolar depression. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.CrossRefGoogle Scholar
55.McIntyre, RS, Mancini, DA, McCann, SM, et al. Randomized, single-blind comparison of topiramate and bupropion SR as add-on therapy in bipolar depression. Paper presented at: 39th Annual Meeting of American College of Neuropsychopharmacology; December 2000; San Juan, Puerto Rico.Google Scholar
56.Marcotte, D. Use of topiramate, a new anti-epileptic, as a mood stabilizer. J Affective Disord. 1998;50:245–251.CrossRefGoogle ScholarPubMed
57.Schlatter, FJ, Soutullo, CA, Cervera-Enguix, S. J Clin Psychopharmacol. 2001;21:464–466.CrossRefGoogle Scholar
58.Emrich, HM. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol. 1990;5(suppl):83–88.Google Scholar
59.Emrich, HM, Dose, M, von Zerssen, D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord. 1985;8:243–250.CrossRefGoogle ScholarPubMed
60.Reinstein, MJ, Sonenberg, JG, Chasanov, MA, et al. Oxcarbazepine and divalproex sodium: a comparison of efficacy and side effects for mania [poster]. Presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.Google Scholar
61.Hummel, B, Stampfer, R, Grunze, H, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-of-on design. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.Google Scholar
62.Kaufman, KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry. 1998;10:181–184.CrossRefGoogle ScholarPubMed
63.Grunze, H, Erfurth, A, Marcuse, A, et al.Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry. 1999;60:759–762.CrossRefGoogle Scholar
64.Schaffer, LC, Schaffer, CB, How, J. The use of tiagabine in the treatment of patients with refractory bipolar disorder. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.Google Scholar
65.Kanba, S, Yagi, G, Kamijma, K, et al.The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:707–715.Google ScholarPubMed
66.Tohen, M, Sanger, TM, McElroy, SL, et al.Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156:702–709.CrossRefGoogle ScholarPubMed
67.Ghaemi, SN, Cherry, EL, Katzow, JA, Goodwin, FK. Does olanzapine have antidepressant properties? A retrospective, preliminary study. Bipolar Disord. 2000;2:196–199.CrossRefGoogle ScholarPubMed
68.Sanger, TM, Grundy, SL, Gibson, J, et al.Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001;62:273–281.CrossRefGoogle ScholarPubMed
69.Aubry, JM, Simon, AE, Bertschy, G. Possible induction of mania and hypomania by olanzapine or risperidone. A critical review of reported cases. J Clin Psychiatry. 2000;61:649–655.CrossRefGoogle ScholarPubMed
70.Segal, J, Berk, M, Brook, S. Risperidone compared with both lithium and haloperidol in mania: a double-blind, randomized, controlled trial. Clin Neuropharmacol. 1998;23:176–80.Google Scholar
71.Grossman, F, Bowden, CL, Okamato, A. Risperidone plus mood stabilizer versus placebo plus mood stabilizer in patients with bipolar disorder: a combined efficacy analysis. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.CrossRefGoogle Scholar
72.Yatham, LN. Risperidone and mood stabilizer combination in acute and continuation treatment of mania. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.CrossRefGoogle Scholar
73.Benabarre, A, Vieta, E, Martinez-Aran, A, et al. Risperidone as adjunctive treatment in mixed mania. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.Google Scholar
74.Shelton, RC, Addington, S, Augenstein, EJ, et al. Risperidone in bipolar depression. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, La.Google Scholar
75.Aubry, JM, Simon, AE, Bertschy, G. Possible induction of mania and hypomania by olanzapine or risperidone. A critical review of reported cases. J Clin Psychiatry. 2000;61:649–655.CrossRefGoogle ScholarPubMed
76.McConville, BJ, Arvanitis, LA, Thyrum, PT, et al.Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61:252–260.CrossRefGoogle ScholarPubMed
77.DelBello, MP, Rosenberg, HL, Hudopohl, AM, et al. Quetiapine as adjunctive treatment for adolescent mania. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.Google Scholar
78.Ghaemi, SN, Goldberg, JF, Ko, JY, et al. Seroquel treatment of rapid-cycling bipolar disorder: an open prospective study. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.CrossRefGoogle Scholar
79.Chisolm, K, Suppes, T. Clinical response to quetiapine add-on for treatment of refractory bipolar disorder. Paper presented at: Fourth International Conference on Bipolar Disorder; June 2001; Pittsburgh, Pa.Google Scholar
80.Keck, PE Jr, Ice, KN, and the Ziprasidone Study Group. Controlled treatment of acute mania with ziprasidone. Paper presented at: Annual Meeting of the American Psychiatric Association; May 2000; Chicago, Ill.Google Scholar
81.Prien, RF, Kupfer, DJ, Mansky, PA, et al.Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry. 1984;41:1096–1104.CrossRefGoogle ScholarPubMed
82.Guille, C, Sachs, GS, Ghaemi, SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2000;61:638–642.CrossRefGoogle ScholarPubMed
83.Frye, MA, Ketter, TA, Leverich, GS, et al.The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9–15.CrossRefGoogle ScholarPubMed